In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of 60 Degrees Pharmaceuticals Inc (NASDAQ: SXTP) closed at $1.63M in the last session, up 659283% from day before closing price of $2.16. In other words, the price has increased by $659283 from its previous closing price. On the day, 0.66 million shares were traded. SXTP stock price reached its highest trading level at $2.15 during the session, while it also had its lowest trading level at $1.91.
Ratios:
We take a closer look at SXTP’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.71 and its Current Ratio is at 3.13. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 03 ’25 when XU CHERYL bought 5,000 shares for $2.88 per share. The transaction valued at 14,410 led to the insider holds 15,816 shares of the business.
XU CHERYL bought 6,000 shares of SXTP for $9,375 on Dec 13 ’24. The Director now owns 52,078 shares after completing the transaction at $1.56 per share. On Dec 12 ’24, another insider, XU CHERYL, who serves as the Director of the company, bought 5,000 shares for $1.82 each. As a result, the insider paid 9,125 and bolstered with 46,078 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SXTP now has a Market Capitalization of 3048882 and an Enterprise Value of 9238751. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.86. Its current Enterprise Value per Revenue stands at 11.515 whereas that against EBITDA is -0.904.
Stock Price History:
The Beta on a monthly basis for SXTP is 2.90, which has changed by -0.8767857 over the last 52 weeks, in comparison to a change of 0.09544468 over the same period for the S&P500. Over the past 52 weeks, SXTP has reached a high of $35.99, while it has fallen to a 52-week low of $1.41. The 50-Day Moving Average of the stock is -19.91%, while the 200-Day Moving Average is calculated to be -49.10%.
Shares Statistics:
According to the various share statistics, SXTP traded on average about 1.63M shares per day over the past 3-months and 158480 shares per day over the past 10 days. A total of 1.47M shares are outstanding, with a floating share count of 1.37M. Insiders hold about 6.91% of the company’s shares, while institutions hold 2.04% stake in the company. Shares short for SXTP as of 1748563200 were 17898 with a Short Ratio of 0.01, compared to 1745971200 on 28622. Therefore, it implies a Short% of Shares Outstanding of 17898 and a Short% of Float of 1.24.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The firm’s stock currently is rated by 1.0 analysts. The consensus estimate for the next quarter is -$1.21, with high estimates of -$1.21 and low estimates of -$1.21.
Analysts are recommending an EPS of between -$4.95 and -$4.95 for the fiscal current year, implying an average EPS of -$4.95. EPS for the following year is -$5.36, with 1.0 analysts recommending between -$5.36 and -$5.36.
Revenue Estimates
According to 1 analysts, the current quarter’s revenue is expected to be $320k. It ranges from a high estimate of $320k to a low estimate of $320k. As of the current estimate, 60 Degrees Pharmaceuticals Inc’s year-ago sales were $124.97kFor the next quarter, 1 analysts are estimating revenue of $380k. There is a high estimate of $380k for the next quarter, whereas the lowest estimate is $380k.
A total of 1 analysts have provided revenue estimates for SXTP’s current fiscal year. The highest revenue estimate was $1.4M, while the lowest revenue estimate was $1.4M, resulting in an average revenue estimate of $1.4M. In the same quarter a year ago, actual revenue was $607.57kBased on 1 analysts’ estimates, the company’s revenue will be $2.22M in the next fiscal year. The high estimate is $2.22M and the low estimate is $2.22M.
